Drug discovery and development depends increasingly on imaging, from traditional microscopy to high-content screening. Moreover, these techniques provide sophisticated capabilities. To make the most use of these tools, researchers need advanced software that provides automation, analysis, and ease-of-use.
An initial review of data from three separate Phase 3 trials did not provide evidence of...
Researchers have found that a history of frequent heartburn was linked to a 78% increased risk...
Forest Laboratories Inc. announced that Howard Solomon, its CEO for the last 36 years, will retire at the end of 2013. Solomon, 85, will step down as president and CEO on Dec. 31, and will resign as chairman at the time of the company's annual shareholder meeting in 2014.
Alkermes said that it was profitable in its fiscal fourth quarter as it received bigger royalty payments and more revenue for drug manufacturing. The Irish company said revenue from manufacturing and royalty payments climbed 33% during the quarter, and its total revenue rose 25%.
Hypoactive sexual desire disorder affects 10% of women in the United States and significantly higher percentages of women who have undergone surgical menopause.There are no U.S. Food and Drug Administration-approved treatments for this large, unmet medical need.
Johnson & Johnson plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017. The company's pipeline of late-stage drugs include a hepatitis C treatment, a long-lasting version of Invega, and several vaccines.
A majority of medical experts on a U.S. Food and Drug Administration panel said that an experimental insomnia drug from Merck & Co. Inc. appears safe and effective, in spite of evidence from company trials that the pill can cause daytime sleepiness and difficulty driving.
Moody's Investors Service has placed Hospira Inc.'s long-term debt rating under review for possible downgrade. The move was based on a concern that the company's performance over the next few years remains uncertain as a result of costs related to its new product strategy and possible regulatory issues.
GlaxoSmithKline is beginning starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and drug-resistant bacteria. Glaxo's partnership will bring the British drugmaker $40 million over the first 18 months.
Pfizer Inc. plans to start selling its remaining stake in the animal health business Zoetis Inc. through a voluntary exchange offer with its shareholders. Shareholders will be able to trade their Pfizer holdings for Zoetis shares at a discount, depending on the number of shares exchanged.
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease. Citi analyst Andrew Baum expects that within 10 years, immunotherapy will form the backbone of 60% of all cancer treatment plans in the developed world.
Gibson Assembly is a rapid and reliable method for the assembly of DNA fragments in a single-tube, isothermal reaction without reliance upon the presence of restriction sites within the target sequence. The technique is readily adaptable for site-directed mutagenesis.
AcelRx Pharmaceuticals Inc. announced that its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval. Patients using the system experienced a significantly greater reduction in pain than those taking a placebo.
GlaxoSmithKline has launched Discovery Fast Track, a competition designed to accelerate academic research into novel therapies. Winners will partner with investigators on GSK’s Discovery Partnerships with Academia team to turn research-stage drug candidates into innovative medicines.
A new study of both computer-created and natural proteins suggests that the number of unique pockets– sites where small molecule pharmaceutical compounds can bind to proteins– is surprisingly small, meaning drug side effects may be impossible to avoid.
A Phase 2a trial of dupilumab showed that the experimental monoclonal antibody has the ability to stick to certain inflammatory proteins and significantly reduce acute breathing problems in patients suffering from moderate-to-severe asthma.
Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.